Jefferies downgraded Deciphera to Hold from Buy with a price target of $25.60, down from $26, after Ono agreed to acquire Deciphera for $25.60 per share in cash. The firm expects the deal to close by Q3, since Ono’s broad cancer pipeline is synergistic and has no real overlap with Deciphera, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential